Medical Research

Investments Medical Research

Technology is beginning to unravel some of the formerly intractable problems of medical research, particularly those related to data. The annotation of just one sequenced human genome accounts for multiple terabytes of data – until recently, a body of information so large and unwieldy that it is a severe bottleneck to those trying to understand and find treatments for diseases like cancer. We are interested in applying our data center expertise to help in the solution of these challenges and particularly, in advancing P4 medicine and speeding the time to cure for researchers.


The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment is home to a comprehensive research laboratory that provides rapid genetic analysis of all patient tumors. By analyzing DNA from tumors extracted during surgery, the Center’s team of scientists and researchers, formed by Dr. Greg Foltz of the Swedish Neuroscience Institute, are able to determine which genes are stimulating tumor growths. From there the team is able to provide custom tailored treatment options to fight reoccurring tumor growth. To date, this kind of individualized patient care improves survivability and provides a higher quality of life.


Implicit Bioscience Ltd is a clinical-stage drug development company headquartered in Brisbane, Australia and with a subsidiary, Implicit Bioscience, Inc., in Seattle.

Established in 2004 by a group of Australian and US industry veterans, the company has assembled a team with significant industry experience across the full range of drug development and commercialization activities, from the life science industry, research and banking sectors. Implicit is focused on acquiring and developing clinical stage immunology based therapeutics. It acquires drugs with proven safety profiles in man, and then uses recent immunology advances to consider new indications for these drugs. The company further derisks the opportunity by achieving substantial non-dilutive funding to support clinical development.


Accium Bioscience is pioneering the use of new accelerator mass spectrometry (AMS) applications to cover a wide range of research, from in vitro cell culture studies to understanding individualized tumor drug uptake in patients. AMS’s ultrasensitive detection platform is capable of quantifying 14C-labeled molecules in the 0.001-100 DPM/mL range.

Accium’s innovations provide the most sensitive AMS service available to the global pharmaceutical and life sciences industry – at least 10,000-fold greater sensitivity compared to other techniques. The increased sensitivity accelerates preclinical and early clinical investigation of new pharmaceuticals, radiotracer distribution studies and studies to investigate metabolism, excretion balance and pharmacokinetics, all without method development or matrix interference.

Accium’s customers use AMS services to overcome challenges they face in drug development, including assessment of pharmacokinetics, metabolism and mass balance. Its innovations make this process more accessible and more affordable than ever before.

Accium launched the first commercial AMS facility in North America in early 2006.